Get the Stockscreener App
6.93
4.21%
0.28
Cartesian Therapeutics Inc stock is traded at $6.93, with a volume of 334.91K.
It is up +4.21% in the last 24 hours and down -10.12% over the past month.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.
See More
Previous Close:
$6.65
Open:
$6.62
24h Volume:
334.91K
Relative Volume:
2.86
Market Cap:
$180.20M
Revenue:
$26.00M
Net Income/Loss:
$-219.71M
P/E Ratio:
-0.1392
EPS:
-49.8
Net Cash Flow:
$-51.37M
1W Performance:
-8.82%
1M Performance:
-10.12%
6M Performance:
-27.36%
1Y Performance:
-68.50%
1-Day Range:
$6.53
$7.00
1-Week Range:
$6.53
$7.73
52-Week Range:
$5.98
$26.50
Cartesian Therapeutics Inc Stock (RNAC) Company Profile
Name
Cartesian Therapeutics Inc
Sector
Industry
Phone
301-348-8698
Address
7495 NEW HORIZON WAY, FREDERICK
Compare RNAC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNAC
Cartesian Therapeutics Inc
|
6.93 | 172.92M | 26.00M | -219.71M | -51.37M | -49.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cartesian Therapeutics Inc Stock (RNAC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-09-25 | Initiated | Wedbush | Outperform |
| Dec-19-24 | Initiated | BTIG Research | Buy |
| Aug-06-24 | Initiated | TD Cowen | Buy |
| Jul-02-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-04-24 | Initiated | Oppenheimer | Outperform |
| May-24-24 | Initiated | Mizuho | Buy |
| Apr-23-24 | Reiterated | H.C. Wainwright | Buy |
| Apr-23-24 | Initiated | Leerink Partners | Outperform |
| Aug-18-23 | Downgrade | SVB Securities | Outperform → Market Perform |
| Jun-14-22 | Reiterated | Needham | Buy |
| Jun-06-22 | Initiated | SVB Leerink | Outperform |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| Jan-26-21 | Upgrade | Mizuho | Neutral → Buy |
| Oct-01-20 | Downgrade | Mizuho | Buy → Neutral |
| Oct-01-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-12-20 | Downgrade | Stifel | Buy → Hold |
| Apr-28-20 | Initiated | H.C. Wainwright | Buy |
| Jan-29-20 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-21-20 | Initiated | William Blair | Outperform |
| Jun-27-18 | Initiated | Janney | Buy |
| Mar-30-17 | Reiterated | UBS | Buy |
View All
Cartesian Therapeutics Inc Stock (RNAC) Latest News
Why Cartesian Therapeutics Inc. (1S70) stock stays undervaluedJuly 2025 Price Swings & Verified Momentum Stock Alerts - Newser
Weekly Earnings: What is the fair value estimate for Cartesian Therapeutics Inc 1S70 stock in 20252025 AllTime Highs & Reliable Volume Spike Trade Alerts - BỘ NỘI VỤ
What is the fair value estimate for Cartesian Therapeutics Inc. (1S70) stock in 2025Bond Market & Verified Momentum Stock Watchlist - Newser
Is Cartesian Therapeutics Inc. (1S70) stock a buy for dividend portfoliosEarnings Trend Report & Weekly Stock Breakout Alerts - Newser
Is Cartesian Therapeutics Inc. stock cheap at current valuationEarnings Growth Report & Real-Time Volume Analysis - Newser
Will Cartesian Therapeutics Inc. (1S70) stock outperform global peers2025 Big Picture & Technical Entry and Exit Alerts - Newser
What makes Cartesian Therapeutics Inc. (1S70) stock appealing to growth investorsQuarterly Profit Review & High Accuracy Buy Signal Tips - Newser
What MACD trends signal for Cartesian Therapeutics Inc. (1S70) stockWeekly Stock Recap & Weekly High Return Forecasts - Newser
Why Cartesian Therapeutics Inc. (1S70) stock remains stableEarnings Risk Report & Community Driven Trade Alerts - Newser
Cartesian Therapeutics, Inc. (RNAC) 7.5% in After-hours: Amid Routine Trading Conditions - Stocks Telegraph
Is Cartesian Therapeutics Inc. stock in correction or buying zoneJuly 2025 Update & Accurate Intraday Trade Tips - moha.gov.vn
Free cash flow per share of Cartesian Therapeutics, Inc. – MUN:1S70 - TradingView
Book value per share of Cartesian Therapeutics, Inc. – MUN:1S70 - TradingView
Is Umiya Tubes Limited Stock Risky in the Current Market EnvironmentInsider Selling Patterns & High Return Capital Gains - earlytimes.in
Will Cartesian Therapeutics Inc. stock deliver better than expected guidance - BỘ NỘI VỤ
Automated Systems Holdings Limited Announces Change in Share Registrar - The Globe and Mail
Brokerages Set Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Target Price at $38.00 - Defense World
Will Cartesian Therapeutics Inc. (1S70) stock outperform energy sector in 2025July 2025 Levels & Weekly High Conviction Ideas - newser.com
Will Cartesian Therapeutics Inc. (1S70) stock attract long term capital inflowsBear Alert & Daily Price Action Insights - newser.com
Is Cartesian Therapeutics Inc. stock a defensive play in 2025July 2025 Snapshot & Target Return Focused Picks - newser.com
How Cartesian Therapeutics Inc. (1S70) stock trades in high volatilityTrade Analysis Report & Risk Managed Trade Strategies - newser.com
Will Cartesian Therapeutics Inc. (1S70) stock recover faster than industryWeekly Stock Analysis & Low Risk Growth Stock Ideas - newser.com
HC Wainwright Has Lowered Expectations for Cartesian Therapeutics (NASDAQ:RNAC) Stock Price - Defense World
Is Cartesian Therapeutics Inc. a candidate for recovery playWeekly Profit Summary & Consistent Return Investment Signals - newser.com
[Form 4] Cartesian Therapeutics, Inc. Insider Trading Activity - Stock Titan
H.C. Wainwright lowers Cartesian Therapeutics stock price target to $30 from $40 By Investing.com - Investing.com South Africa
Dir Singer Gifts 20,000 Of Cartesian Therapeutics Inc [RNAC] - TradingView
Ranking Cartesian Therapeutics Inc. among high performing stocks via tools2025 Buyback Activity & Fast Gain Stock Trading Tips - newser.com
H.C. Wainwright lowers Cartesian Therapeutics stock price target to $30 from $40 - Investing.com Canada
What indicators show strength in Cartesian Therapeutics Inc.July 2025 Recap & AI Powered Buy and Sell Recommendations - newser.com
HC Wainwright & Co. Maintains Cartesian Therapeutics (RNAC) Buy Recommendation - Nasdaq
How Cartesian Therapeutics Inc. stock performs during Fed tightening cyclesQuarterly Portfolio Report & Entry and Exit Point Strategies - newser.com
HC Wainwright & Co. Lowers Price Target for RNAC Despite Maintai - GuruFocus
Cartesian Therapeutics (RNAC) Receives Lowered Price Target but Retains Buy Rating - GuruFocus
Is Cartesian Therapeutics Inc. stock supported by strong fundamentals2025 Biggest Moves & Step-by-Step Swing Trade Plans - newser.com
Cartesian Therapeutics Inc Stock (RNAC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):